Pulse Biosciences (PLSE) announced the enrollment of the first patient in its NANOCLAMP AF study for the treatment of atrial fibrillation. The successful first procedure was completed at St. Helena Hospital in St. Helena, California, with the nPulse Cardiac Surgical System following its recent FDA IDE approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE: